主页 > 医药科学 >
【drug-news】他汀药不会增加患癌症风险
Study Shows Cholesterol-Lowering Drugs Not Guilty of Cancer Risk
By Daniel J. DeNoon
WebMD Health News
Reviewed by Louise Chang, MD
Aug. 20, 2008 -- Cholesterol-lowering statin drugs do not increase cancer risk, says Tufts University's Richard Karas, MD, who last year warned of a possible risk.
The earlier warning was based on data suggesting that people achieved the lowest "bad" LDL cholesterol levels while taking statin drugs had the highest cancer risk.
But a more complete analysis of the data, from 15 large, randomized statin studies including nearly 52,000 patients, shows no link between statins and cancer risk.
"When you put all of the information together, there is no evidence that statins increase the risk of cancer," Karas says in a news release. "This study should reassure those taking statins that they are not increasing their risk of cancer by trying to reduce their risk of cardiovascular disease."
In fact, the studies showed that statins lowered LDL cholesterol levels by an average of 40 points. This cholesterol reduction came with no increase in cancer risk. Studies suggest that every 40-point reduction in LDL cholesterol reduces a person's risk of heart disease by 20%.
Statin drugs include Lescol, Mevacor, Lipitor, Pravachol, Crestor, and Zocor.
Karas and colleagues did not set out to look at cancer risk. They were analyzing clinical trial data to evaluate other possible side effects and were asked to include cancer in their analysis.
Previous studies have linked very low LDL cholesterol to cancer risk. The Karas team confirmed this link. They also showed that statins -- regardless of dose -- had no effect on cancer risk.
Whatever link there may be between low LDL cholesterol levels and cancer, they conclude, it "is not driven by statins."
"Statin therapy, despite producing marked reductions in LDL cholesterol, is not associated with an increased risk of cancer," Karas and colleagues write.
The new findings appear in the Journal of the American College of Cardiology, published online ahead of print on Aug. 20. 他汀药不会增加患癌症风险? 他汀药不会增加患癌症风险
Statins: No Cancer Risk
Study Shows Cholesterol-Lowering Drugs Not Guilty of Cancer Risk
研究证明降脂药物不会增加癌症发病率
By Daniel J. DeNoon
Daniel J. DeNoon
WebMD Health News
健康新闻网
Reviewed by Louise Chang, MD
Aug. 20, 2008 -- Cholesterol-lowering statin drugs do not increase cancer risk, says Tufts University's Richard Karas, MD, who last year warned of a possible risk.
2008.8.20--- Tufts大学的 Richard Karas医学博士说：去年他汀类降脂药物被认为可增加癌症患病风险，现在证明这一说法不正确。
The earlier warning was based on data suggesting that people achieved the lowest "bad" LDL cholesterol levels while taking statin drugs had the highest cancer risk.
But a more complete analysis of the data, from 15 large, randomized statin studies including nearly 52,000 patients, shows no link between statins and cancer risk.
早先关于服用他汀类药物降低低密度脂蛋白的患者患癌风险几率增加的声明从实验数据中得出，但是更广泛的分析数据从15项包括近52000位患者随机他汀研究显示得出患癌几率与他汀的服用无任何直接关系。
"When you put all of the information together, there is no evidence that statins increase the risk of cancer," Karas says in a news release. "This study should reassure those taking statins that they are not increasing their risk of cancer by trying to reduce their risk of cardiovascular disease."
Karas在新闻发布会上说：当你把所有的信息综合在一起，可以得出他汀类与增加患癌几率之间没有明显的证据，研究可以肯定服用他汀类降脂可降低心血管疾病的发生率，并且不能增加患癌几率。
In fact, the studies showed that statins lowered LDL cholesterol levels by an average of 40 points. This cholesterol reduction came with no increase in cancer risk. Studies suggest that every 40-point reduction in LDL cholesterol reduces a person's risk of heart disease by 20%.
事实上，研究证明他汀降低低密度脂蛋白水平，大约40个百分点，降脂却没增加患癌风险几率，研究表明，降低40%的低密度脂蛋白可减少20%患心血管疾病的几率。
Statin drugs include Lescol, Mevacor, Lipitor, Pravachol, Crestor, and Zocor.
他汀类药物包括：来适可、美降脂、立普妥、普拉固、舒降之、Crestor。
Karas and colleagues did not set out to look at cancer risk. They were analyzing clinical trial data to evaluate other possible side effects and were asked to include cancer in their analysis.
Karas和他的同事们没有观察患癌风险率，他们分析了临床试验数据来评价其他的侧面影响，并且包括患癌几率的分析。
Previous studies have linked very low LDL cholesterol to cancer risk. The Karas team confirmed this link. They also showed that statins -- regardless of dose -- had no effect on cancer risk.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-11-22 17:11
医学,生命科学网